Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Mar;14(3):297-302.
doi: 10.3779/j.issn.1009-3419.2011.03.18.

[The detection methods of EGFR mutations in non-small cell lung cancer]

[Article in Chinese]
Xinyu Zhang  1 , Guiyang Liu, Xiaoguang Zhu, Weilan Wang
Affiliations
Review

[The detection methods of EGFR mutations in non-small cell lung cancer]

[Article in Chinese]
Xinyu Zhang et al. Zhongguo Fei Ai Za Zhi. 2011 Mar.
No abstract available

PubMed Disclaimer

References

    1. Lynch T, Bell D, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. doi: 10.1056/NEJMoa040938. - DOI - PubMed
    1. Paez J, Janne P, Lee J, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. http://www.doc88.com/p-7347017221581.html. Science. 2004;304(4):1497–1500. - PubMed
    1. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung can-cers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. PNAS. 2004;101(36):13306–13311. doi: 10.1073/pnas.0405220101. - DOI - PMC - PubMed
    1. Sae WH, Tae YK, Pil GH, et al. Predictive and prognostic impact of epidermal growthfactor receptor mutation in non-small-cell lung cancer Patients treated with Gefitinib. J Clin Oncol. 2005;23(11):2493–2501. doi: 10.1200/JCO.2005.01.388. - DOI - PubMed
    1. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005;11(16):5878–5885. doi: 10.1158/1078-0432.CCR-04-2618. - DOI - PubMed

MeSH terms